Docket No.: 20855/0205063-US0

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Tadaaki Ohgi et al.

Application No.: National Phase of

PCT/JP2005/000974

Filed: Concurrently Herewith Art Unit: N/A

For: RIBONUCLEIC ACID COMPOUND AND

METHOD OF LIQUID-PHASE SYNTHESIS OF OLIGONUCLEIC ACID COMPOUND

Confirmation No.: N/A

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information

Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: July 26, 2006

Respectfully submitted,

Dianna Goldenson

Registration No.: 52,949 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	Substitute for form 1449A/B/PTO			Complete if Known		
- 				Application Number	Not Yet Assigned	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	STATEMENT E	3Y /	APPLICANT	First Named Inventor	Tadaaki Ohgi	
1				Art Unit	N/A	
l	(Use as many she	∍ets as	i necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	20855/0205063-US0	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where	
		Number-Kind Code ² (# known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	ВА	WO-02/079215-A1	10-10-2002	ISIS PHARMACEUTICALS, INC., et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	SHIGENORI IWAI, et al., Large Scale Synthesis of Oligoribonucleotides on a Solid Support: Synthesis of a Catalytic RNA Duplex, Tetrahedron Vol. 46, No. 19, pp. 6673-6688, 1990	
	СВ	FRANCISCO MORIS, et al., A Useful and Versatile Procedure for the Acylation of Nucleosides through an Enzymatic Reaction, J. Org. Chem. 1993, Vol. 58, No. 3, pp. 653-660	
	CC	J. H. VAN BOOM, et al., Use of Levulinic Acid in the Protection of Oligonucleotides <u>via</u> the Modified Phosphotriester Method: Synthesis of Decaribonucleotide U-A-U-A-U-A-U-A, Tetrahedron Letters No. 52, pp. 4875-4878, 1976	
	CD	J. H. VAN BOOM, et al., Synthesis of Oligonucleotides with Sequences Identical with or Analogous to the 3'-End of 16S Ribosomal RNA of Escherichia Coli: Preparation of U-C-C-U-U-A and A-C-C-U-C-C-U-U-A via the Modified Phosphotriester Method, Tetrahedron Vol. 34, pp. 1999-2007, 1978	
	CE	J. A. J. DEN HARTOG, et al., Synthesis of oligoribonucleotides with sequences identical to the nucleation region of Tobacco Mosaic Virus RNA: preparation of AAG, AAGAAG and AAGAAGUUG via phosphotriester methods, Recueil, Journal of the Royal Netherlands Chemical Society, 100/9, September 1981, pp. 320-330	
	CF	J. A. J. DEN HARTOG, et al., Chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 3'/2'-phosphorylated heptamer sequence of <i>E. coli</i> tRNA chemical synthesis of a 5'- and 5'-	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.